These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 34496886)

  • 1. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
    Jiang W; Pan S; Chen X; Wang ZW; Zhu X
    Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs.
    Ashrafizadeh M; Zarrabi A; Hushmandi K; Zarrin V; Moghadam ER; Zabolian A; Tavakol S; Samarghandian S; Najafi M
    Life Sci; 2020 Sep; 256():117899. PubMed ID: 32504749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
    Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
    Front Immunol; 2019; 10():1337. PubMed ID: 31258527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
    Wu Y; Chen W; Xu ZP; Gu W
    Front Immunol; 2019; 10():2022. PubMed ID: 31507611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
    Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
    Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
    Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
    Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
    Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs.
    Ding L; Lu S; Li Y
    Pathol Oncol Res; 2020 Apr; 26(2):651-663. PubMed ID: 31748880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.
    Salmaninejad A; Valilou SF; Shabgah AG; Aslani S; Alimardani M; Pasdar A; Sahebkar A
    J Cell Physiol; 2019 Aug; 234(10):16824-16837. PubMed ID: 30784085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
    Liu Q; Guan Y; Li S
    Mol Cancer; 2024 Sep; 23(1):183. PubMed ID: 39223527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
    Jiang Y; Hong K; Zhao Y; Xu K
    Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.
    Cui JW; Li Y; Yang Y; Yang HK; Dong JM; Xiao ZH; He X; Guo JH; Wang RQ; Dai B; Zhou ZL
    Biomed Pharmacother; 2024 Feb; 171():116203. PubMed ID: 38280330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
    Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
    Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.